No Randomized Controlled Trials Presented at the ESC This Month
There is no information available about randomized controlled trials presented at the European Society of Cardiology (ESC) this month in the provided evidence.
The evidence provided does not contain any information about current ESC conferences or recently presented randomized controlled trials. The most recent evidence about ESC content is from 2023 1, which mentions studies presented at the 2023 ESC Congress, but does not provide information about trials presented in the current month.
Analysis of Available Evidence
The evidence provided consists primarily of:
- ESC guidelines from 2013 on stable coronary artery disease 2
- ESC guidelines from 2016 on heart failure 2
- A summary of selected studies from the 2023 ESC Congress 1
- Older publications about ESC guidelines and conferences from 2006-2022 3, 4, 5, 6
None of these sources contain information about randomized controlled trials presented at the ESC in the current month.
What Was Presented at the Most Recent ESC Congress (2023)
While not from the current month, the most recent information available is from the 2023 ESC Congress 1, which featured:
- NATURE-PARADOX: A naturally randomized trial using genetic data from UK Biobank to evaluate cumulative LDL-C exposure and cardiovascular events
- Safety and efficacy data on inclisiran (PCSK9-interfering mRNA)
- Data on new PCSK9 inhibitors: recaticimab (oral) and lerodalcibep (subcutaneous)
- Phase 1 trial on muvalaplin (oral lipoprotein(a) inhibitor)
- ASCVD risk prediction algorithm for Asian populations using SCORE2 data
- Long-term follow-up of the CLEAR outcomes trial on bempedoic acid
To obtain information about randomized controlled trials presented at the ESC in the current month, you would need to consult the official ESC website, recent medical news sources, or conference proceedings that are not included in the provided evidence.